PHOENIX — Frexalimab, a second-generation anti-CD40 ligand monoclonal antibody offers extended tight adjust of a pair of sclerosis (MS) whether or now no longer measured by relapse or brain imaging at 2-one year apply-up, results of an delivery-designate extension (OLE) of a portion 2 trial showed. “At week 96, there used to be almost complete suppression of latest gadolinium-enhancing lesions with very identical pattern …
Learn More
2025-06-09
